Zachary Veitch1,2, Domen Ribnikar3, Derek Tilley4, Patricia A Tang5, Karen King6, Philippe L Bedard7, Sasha Lupichuk5, David W Cescon7. 1. Department of Medical Oncology and Hematology, St Michael's Hospital, Toronto, ON, Canada. veitchz@rvh.on.ca. 2. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada. veitchz@rvh.on.ca. 3. Medical Oncology Department, Institute of Oncology Ljubljana, Ljubljana, Slovenia. 4. Cancer Care Alberta, Alberta Health Services, Calgary, AB, Canada. 5. Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada. 6. Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada. 7. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Abstract
BACKGROUND: Long-term response to HER2-targeted therapies is infrequent in metastatic breast cancer (MBC). We evaluated clinical characteristics of HER2-positive MBC patients with no evidence of disease (NED) vs residual disease (RES) experiencing long-term response to first-line HER2-targeted therapy. METHODS: Patients receiving first-line chemotherapy-trastuzumab (CT) or taxane-trastuzumab-pertuzumab (THP) with response duration ≥2-fold higher than in phase II/III trials (CT [18.2 months]; THP [40.4 months]) were included. Clinical characteristics and radiographic review for NED or RES was evaluated by Cox-regression (hazard ratio; HR) or Kaplan-Meier (log-rank). Characteristics associated with NED were evaluated by logistic regression (Odds; OR). RESULTS: From 01/2005-01/2016, N = 103 (4.6%) patients were identified. In multivariate analyses, NED (N = 46) showed improved progression-free (PFS) and overall survival (OS) [p < 0.001] versus RES (N = 57), with high 5-year PFS/OS for NED (93.2%/97.4%) relative to RES (10.6%/61.3%). Premenopausal status (p = 0.006), de-novo metastases (p = 0.002), and no palliative radiotherapy (p = 0.01) were associated with NED. Overall, 6/7 (85.7%) patients with NED were alive and disease-free after discontinuing HER2 treatment (≥1 year) versus 1/17 (5.9%) with RES. CONCLUSIONS: Long-term responders with NED have better survival compared to RES. Premenopausal status and de novo metastatic disease are associated with NED. Prospective studies of HER2 therapy discontinuation with NED in MBC are warranted.
BACKGROUND: Long-term response to HER2-targeted therapies is infrequent in metastatic breast cancer (MBC). We evaluated clinical characteristics of HER2-positive MBC patients with no evidence of disease (NED) vs residual disease (RES) experiencing long-term response to first-line HER2-targeted therapy. METHODS: Patients receiving first-line chemotherapy-trastuzumab (CT) or taxane-trastuzumab-pertuzumab (THP) with response duration ≥2-fold higher than in phase II/III trials (CT [18.2 months]; THP [40.4 months]) were included. Clinical characteristics and radiographic review for NED or RES was evaluated by Cox-regression (hazard ratio; HR) or Kaplan-Meier (log-rank). Characteristics associated with NED were evaluated by logistic regression (Odds; OR). RESULTS: From 01/2005-01/2016, N = 103 (4.6%) patients were identified. In multivariate analyses, NED (N = 46) showed improved progression-free (PFS) and overall survival (OS) [p < 0.001] versus RES (N = 57), with high 5-year PFS/OS for NED (93.2%/97.4%) relative to RES (10.6%/61.3%). Premenopausal status (p = 0.006), de-novo metastases (p = 0.002), and no palliative radiotherapy (p = 0.01) were associated with NED. Overall, 6/7 (85.7%) patients with NED were alive and disease-free after discontinuing HER2 treatment (≥1 year) versus 1/17 (5.9%) with RES. CONCLUSIONS: Long-term responders with NED have better survival compared to RES. Premenopausal status and de novo metastatic disease are associated with NED. Prospective studies of HER2 therapy discontinuation with NED in MBC are warranted.
Authors: David Cameron; Martine J Piccart-Gebhart; Richard D Gelber; Marion Procter; Aron Goldhirsch; Evandro de Azambuja; Gilberto Castro; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Nedal Al-Sakaff; Sabine Lauer; Eleanor McFadden; Brian Leyland-Jones; Richard Bell; Mitch Dowsett; Christian Jackisch Journal: Lancet Date: 2017-02-17 Impact factor: 79.321
Authors: Jashodeep Datta; Megan Fracol; Matthew T McMillan; Erik Berk; Shuwen Xu; Noah Goodman; David A Lewis; Angela DeMichele; Brian J Czerniecki Journal: JAMA Oncol Date: 2016-02 Impact factor: 31.777
Authors: Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; George Sledge; Charles E Geyer; Silvana Martino; Priya Rastogi; Julie Gralow; Sandra M Swain; Eric P Winer; Gerardo Colon-Otero; Nancy E Davidson; Eleftherios Mamounas; Jo Anne Zujewski; Norman Wolmark Journal: J Clin Oncol Date: 2014-10-20 Impact factor: 44.544
Authors: Sandra M Swain; José Baselga; Sung-Bae Kim; Jungsil Ro; Vladimir Semiglazov; Mario Campone; Eva Ciruelos; Jean-Marc Ferrero; Andreas Schneeweiss; Sarah Heeson; Emma Clark; Graham Ross; Mark C Benyunes; Javier Cortés Journal: N Engl J Med Date: 2015-02-19 Impact factor: 91.245
Authors: Udai Banerji; Carla M L van Herpen; Cristina Saura; Fiona Thistlethwaite; Simon Lord; Victor Moreno; Iain R Macpherson; Valentina Boni; Christian Rolfo; Elisabeth G E de Vries; Sylvie Rottey; Jill Geenen; Ferry Eskens; Marta Gil-Martin; Ellen C Mommers; Norbert P Koper; Philippe Aftimos Journal: Lancet Oncol Date: 2019-06-27 Impact factor: 41.316
Authors: Jashodeep Datta; Erik Berk; Shuwen Xu; Elizabeth Fitzpatrick; Cinthia Rosemblit; Lea Lowenfeld; Noah Goodman; David A Lewis; Paul J Zhang; Carla Fisher; Robert E Roses; Angela DeMichele; Brian J Czerniecki Journal: Breast Cancer Res Date: 2015-05-23 Impact factor: 6.466